secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edesa Biotech, Inc. (EDSA)
CIK:        0001540159
Form:       8-K
Filed at:   2025-09-30T23:59:59+00:00
Accession:  0001171843-25-006188
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 2.03
LLM model:  deepseek-v4-flash:cloud@v2

Edesa Biotech amends CAD$23M gov't agreement, extends timeline to Dec 2028, shifts EB05 focus to general ARDS
--------------------------------------------------------------------------------

- Project completion extended to December 31, 2028 (from December 31, 2025); agreement expiration extended to later of Dec 2045 or last repayment.
- First annual repayment due in 2032 (from 2029) and only if the Company earns gross revenue.
- Clinical focus for EB05 changed to general ARDS from COVID-19 induced ARDS; company gains access to fully funded US government platform study.
- Amendment adds reporting requirements on similar EB05 development projects and updates milestones/timelines.
- Government of Canada committed up to CAD$23M ($17M USD) in partially repayable funding under original agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1540159/000117184325006188/0001171843-25-006188-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1540159/000117184325006188/f8k_093025.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-006188

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer